Chemocentryx reported $-37735000 in EBITDA for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebitda Change
Alexion Pharmaceuticals ALXN:US $ 892.3M 186.4M
Alnylam Pharmaceuticals ALNY:US $ -134.35M 39.3M
Amgen AMGN:US $ 3188M 218M
AstraZeneca AZN:LN 2149M 322M
Bayer BAYN:GR € 3035M 1119M
Biogen BIIB:US $ 1147.6M 41.7M
Biomarin Pharmaceutical BMRN:US $ 41.16M 14.24M
Bristol Myers Squibb BMY:US $ 5679M 455M
Chemocentryx CCXI:US $ -37.74M 8.52M
GlaxoSmithKline GSK:LN 2626M 584M
Glaxosmithkline GSK:US $ 2626M 584M
Johnson & Johnson JNJ:US $ 8103M 786M
Macrogenics MGNX:US $ -37498000 11.07M
Mirati Therapeutics MRTX:US $ -163.78M 31.65M
Novartis NOVN:VX SF 4772M 423M
Omeros OMER:US $ -23661000 6.56M
Pfizer PFE:US $ 7593M 610M
Sarepta Therapeutics SRPT:US $ -159.13M 26.19M
Teva Pharmaceutical TEVA:IT 1.14B 34M
YTE INCY:US $ 169.77M 41.12M